Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era

Satoshi Yamasaki; Yutaka Shimazu; Yukiko Misaki; Makoto Onizuka; Masashi Sawa; Yoshinobu Kanda; Takahiro Fukuda; Chizuko Hashimoto; Makoto Yoshimitsu; Junya Kanda; Yoshiko Atsuta; Shinichi Kako

doi:10.1038/s41598-026-47347-3

Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era

Sci Rep. 2026 Apr 5. doi: 10.1038/s41598-026-47347-3. Online ahead of print.

Authors

Affiliations

¹ Department of Hematology, St. Mary's Hospital, 422 Tsubukuhonmachi, Kurume, Fukuoka, 830-8543, Japan. yamas009@gmail.com.
² Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
³ Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
⁴ Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
⁵ Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
⁶ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
⁷ Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
⁸ Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
⁹ Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
¹⁰ Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagoya, Japan.

PMID: 41936620
DOI: 10.1038/s41598-026-47347-3

No abstract available

Keywords: Allogeneic hematopoietic cell transplantation; Autologous hematopoietic cell transplantation; Ibrutinib; Mantle cell lymphoma; Relapsed or refractory.